全文获取类型
收费全文 | 54778篇 |
免费 | 4839篇 |
国内免费 | 2845篇 |
专业分类
耳鼻咽喉 | 495篇 |
儿科学 | 1457篇 |
妇产科学 | 606篇 |
基础医学 | 4242篇 |
口腔科学 | 1696篇 |
临床医学 | 6333篇 |
内科学 | 12629篇 |
皮肤病学 | 1298篇 |
神经病学 | 2569篇 |
特种医学 | 2181篇 |
外国民族医学 | 1篇 |
外科学 | 4892篇 |
综合类 | 8900篇 |
现状与发展 | 11篇 |
一般理论 | 4篇 |
预防医学 | 6068篇 |
眼科学 | 950篇 |
药学 | 4028篇 |
31篇 | |
中国医学 | 3038篇 |
肿瘤学 | 1033篇 |
出版年
2024年 | 117篇 |
2023年 | 1231篇 |
2022年 | 2087篇 |
2021年 | 3084篇 |
2020年 | 2981篇 |
2019年 | 2299篇 |
2018年 | 2133篇 |
2017年 | 2099篇 |
2016年 | 2278篇 |
2015年 | 2073篇 |
2014年 | 4059篇 |
2013年 | 4235篇 |
2012年 | 3372篇 |
2011年 | 3659篇 |
2010年 | 2865篇 |
2009年 | 2700篇 |
2008年 | 2751篇 |
2007年 | 2695篇 |
2006年 | 2295篇 |
2005年 | 1985篇 |
2004年 | 1564篇 |
2003年 | 1408篇 |
2002年 | 1159篇 |
2001年 | 1082篇 |
2000年 | 865篇 |
1999年 | 640篇 |
1998年 | 631篇 |
1997年 | 513篇 |
1996年 | 366篇 |
1995年 | 443篇 |
1994年 | 388篇 |
1993年 | 280篇 |
1992年 | 293篇 |
1991年 | 249篇 |
1990年 | 193篇 |
1989年 | 212篇 |
1988年 | 198篇 |
1987年 | 180篇 |
1986年 | 145篇 |
1985年 | 112篇 |
1984年 | 105篇 |
1983年 | 60篇 |
1982年 | 70篇 |
1981年 | 45篇 |
1980年 | 40篇 |
1979年 | 48篇 |
1978年 | 32篇 |
1977年 | 33篇 |
1976年 | 35篇 |
1974年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 189 毫秒
1.
2.
3.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
4.
《Bulletin du cancer》2023,110(2):145-150
5.
角膜移植为治疗角膜盲的主要手段,而角膜移植排斥则是决定角膜植片存活时间和病人术后视力的关键。角膜得益于其特殊的眼前节“免疫赦免”状态,使得角膜移植能够在众多器官移植中享有极低的排斥率,然而排斥反应发生的风险依然存在。当机体处于遗传物质异常的特殊状态时,宿主将通过宏观调控“免疫赦免”状态对植片的保护作用或受体对移植物排异产生的有害作用,延迟或促进角膜移植排斥反应的发生,进而影响移植物的存活时间和透明度。该文综述与角膜移植排斥相关的多种全身性遗传疾病,总结全身性遗传疾病对角膜移植排斥的影响,浅析其发生的病理生理学机制以及诊疗的特殊性。 相似文献
6.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
7.
8.
9.
《Revista brasileira de otorrinolaringologia (English ed.)》2020,86(3):321-326
IntroductionMany studies have been done on proteomics, genomics, epigenetic, immunogenetics in many body fluids. Among these, circulating cell-free DNA (ccfDNA) entered the literature in 1948, but it has not been studied for many years due to technological deficiencies. Following recent advances, geno-metastasis has been mentioned and new research is needed in this area. ccfDNA is known to be an important biomolecule in this regard.ObjectiveThe presence of cell-free DNA in the circulatory system may offer a tremendous opportunity to provide novel biomarkers for thyroid diseases. This experimental study was conducted to determine the amount of ccfDNA in different thyroid diseases, then to evaluate whether the ccfDNA concentration varied between the disease groups and control group.MethodsIn total, we included 121 individuals in the present study. We collected blood samples and then determined the ccfDNA concentration in plasma of collected blood samples from three groups: thyroiditis (n = 33), benign (n = 37), and malignant (n = 30) and from a control group (n = 21).ResultsThe median values of the ccfDNA groups were found as 1610, 1665, 1685 and 576 ng/mL for the thyroiditis, benign, malign, and control groups, respectively. Findings showed that the ccfDNA of the three groups was significantly higher than the control (p < 0.0001). Each group was compared in terms of ccfDNA and the p-values of benign-thyroiditis, benign-malign, and thyroiditis-malign were 0.09, 0.65, and 0.29, respectively.ConclusionsThe clear differences between thyroid diseases and controls suggest that ccfDNA is worthy of attention as a biomarker for further evaluation of different thyroid diseases. Likewise, it might indicate a clear tendency that ccfDNA can also be used to distinguish different thyroid diseases. 相似文献